{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:56:07Z","timestamp":1793314567906,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Although the dual anti-HER2 therapy, namely, pertuzumab plus trastuzumab and docetaxel, has shown promising results in HER2+ breast cancer patients, whether the dose, efficacy and safety of this treatment differs from those of other pertuzumab-based dual anti-HER2 therapies remain controversial. This systematic review evaluates the efficacy and safety of H (trastuzumab or trastuzumab emtansine \u00b1 chemotherapy)\u2009+\u2009P (pertuzumab) compared with those of H in HER2+ breast cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive search was performed to identify eligible studies comparing the efficacy and safety of H\u2009+\u2009P versus H. The pathologic complete response (pCR), median progression-free survival (PFS) and overall survival (OS) were the primary outcomes, and safety was the secondary outcome. A subgroup analysis of pCR according to hormone receptor (HR) status was performed. All analyses were conducted using STATA 11.0.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-six studies (9872 patients) were identified. In the neoadjuvant setting, H\u2009+\u2009P significantly improved the pCR [odds ratio (OR)\u2009=\u20091.33; 95% confidence interval (CI), 1.08\u20131.63;<jats:italic>p<\/jats:italic>\u2009=\u20090.006]. In the metastatic setting, H\u2009+\u2009P significantly improved PFS [hazard ratios (HRs)\u2009=\u20090.75; 95% CI, 0.68\u20130.84;<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001]. There was a trend towards better OS but that it did not reach statistical significance (HRs\u2009=\u20090.81; 95% CI, 0.64\u20131.03;<jats:italic>p<\/jats:italic>\u2009=\u20090.082). A subgroup analysis revealed that the HER2+\/HR- patients who received H\u2009+\u2009P showed the highest increase in the pCR. Rash, diarrhea, epistaxis, mucosal inflammation, and anemia were significantly more frequently observed with H\u2009+\u2009P than with H, whereas myalgia was less frequent (OR\u2009=\u20090.91; 95% CI, 0.82\u20131.01;<jats:italic>p<\/jats:italic>\u2009=\u20090.072), and no significant difference in cardiac toxicity was observed between these therapies (OR\u2009=\u20091.26; 95% CI, 0.81\u20131.95;<jats:italic>P<\/jats:italic>\u2009=\u20090.309).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study confirms that H\u2009+\u2009P is superior to H in the (neo)adjuvant treatment of HER2+ breast cancer, and increase the risk of acceptable and tolerable toxicity (rash, diarrhea, epistaxis, mucosal inflammation, and anemia).<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>A systematic review protocol was registered with PROSPERO (identification number:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=110415\">CRD42018110415<\/jats:ext-link>).<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-019-6132-0","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T13:33:36Z","timestamp":1571664816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Shanshan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2340-8941","authenticated-orcid":false,"given":"Mingxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"key":"6132_CR1","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1200\/JCO.2013.54.0948","volume":"32","author":"SH Giordano","year":"2014","unstructured":"Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. Clin Oncol. 2014;32:2078\u201399.","journal-title":"Clin Oncol"},{"key":"6132_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783\u201392.","journal-title":"N Engl J Med"},{"key":"6132_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1097\/CAD.0b013e328352d292","volume":"23","author":"CG Murphy","year":"2012","unstructured":"Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anti-Cancer Drugs. 2012;23:765\u201376.","journal-title":"Anti-Cancer Drugs"},{"key":"6132_CR4","first-page":"103","volume":"6","author":"DR Oostra","year":"2014","unstructured":"Oostra DR, Macrae ER. Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer. Breast Cancer. 2014;6:103\u201313.","journal-title":"Breast Cancer"},{"key":"6132_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrc2656","volume":"9","author":"J Baselga","year":"2009","unstructured":"Baselga J, Swain SM. Novel anticancer targets:revisiting ERBB2 and discovering ERBB3. NatRev Cancer. 2009;9:463\u201375.","journal-title":"NatRev Cancer"},{"key":"6132_CR6","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","volume":"69","author":"W Scheuer","year":"2009","unstructured":"Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced antitumor activity of trastuzumaband pertuzumab combination treatment on HER2-positive human xenograft tumor models. CancerRes. 2009;69:9330\u20136.","journal-title":"CancerRes."},{"key":"6132_CR7","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-13-0518","volume":"19","author":"O Metzger-Filho","year":"2013","unstructured":"Metzger-Filho O, Winer EP, Krop I. Pertuzumab: optimizing HER2 blockade. Clin Cancer Res. 2013;19:5552\u20136.","journal-title":"Clin Cancer Res"},{"key":"6132_CR8","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1038\/onc.2008.13","volume":"27","author":"Z Cai","year":"2008","unstructured":"Cai Z, Zhang G, Zhou Z, et al. Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2\/neu and the EGFR-p185her2\/neu complexes. Oncogene. 2008;27:3870\u20134 https:\/\/doi.org\/10.1038\/onc.2008.13 .","journal-title":"Oncogene."},{"issue":"26","key":"6132_CR9","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1200\/JCO.2016.70.6267","volume":"35","author":"A Urruticoechea","year":"2017","unstructured":"Urruticoechea A, Rizwanullah M, Im SA, Mu\u00f1oz M, et al. Randomized phase III trial of Trastuzumab plus Capecitabine with or without Pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast Cancer who experienced disease progression during or after Trastuzumab-based therapy. J Clin Oncol. 2017;35(26):3030\u20138.","journal-title":"J Clin Oncol"},{"issue":"9","key":"6132_CR10","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1245\/s10434-017-5863-x","volume":"24","author":"P Beitsch","year":"2017","unstructured":"Beitsch P, Whitworth P, Baron P, et al. Pertuzumab\/Trastuzumab\/CT versus Trastuzumab\/CT therapy for HER2+ breast Cancer: results from the prospective neoadjuvant breast registry symphony trial (NBRST). Ann Surg Oncol. 2017;24(9):2539\u201346.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"6132_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/cpdd.9","volume":"2","author":"M Gupta","year":"2013","unstructured":"Gupta M, Wang B, Carrothers TJ, Girish S, et al. Effects of Trastuzumab Emtansine (T-DM1) on QT interval and safety of Pertuzumab plus T-DM1 in patients with previously treated human epidermal growth factor receptor 2-positive metastatic breast Cancer. Clin Pharmacol Drug Dev. 2013;2(1):11\u201324.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"6132_CR12","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ."},{"issue":"7","key":"6132_CR13","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/annonc\/mdw157","volume":"27","author":"M Martin","year":"2016","unstructured":"Martin M, Fumoleau P, Dewar JA, Garcia-Saenz JA, et al. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib\/IIa study. Ann Oncol. 2016;27(7):1249\u201356.","journal-title":"Ann Oncol"},{"key":"6132_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.breast.2017.06.015","volume":"35","author":"K Araki","year":"2017","unstructured":"Araki K, Fukada I, Yanagi H, Ito Y, et al. First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer. Breast. 2017;35:78\u201384.","journal-title":"Breast."},{"issue":"1","key":"6132_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25\u201332.","journal-title":"Lancet Oncol"},{"issue":"7","key":"6132_CR16","first-page":"702","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast Cancer. N Engl J Med. 2017;377(7):702.","journal-title":"N Engl J Med"},{"issue":"6","key":"6132_CR17","doi-asserted-by":"publisher","first-page":"e1283","DOI":"10.1016\/j.clbc.2018.07.008","volume":"18","author":"RK Murthy","year":"2018","unstructured":"Murthy RK, Raghavendra AS, Hess KR, Ueno NT, et al. Neoadjuvant Pertuzumab-containing regimens improve pathologic complete response rates in stage II to III HER-2\/neu-positive breast Cancer: a retrospective, single institution experience. Clin Breast Cancer. 2018;18(6):e1283\u20138.","journal-title":"Clin Breast Cancer"},{"issue":"28","key":"6132_CR18","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1200\/JCO.2017.76.7863","volume":"36","author":"M Rimawi","year":"2018","unstructured":"Rimawi M, Ferrero J-M, de la Haba-Rodriguez J, et al. First-line Trastuzumab plus an aromatase inhibitors, with or without Pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast Cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol. 2018;36(28):2826\u201335.","journal-title":"J Clin Oncol"},{"key":"6132_CR19","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"6132_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13058-016-0691-7","volume":"18","author":"IE Krop","year":"2016","unstructured":"Krop IE, Modi S, LoRusso PM, Elias A, et al. Phase 1b\/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res. 2016;18(1):34.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"6132_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","volume":"35","author":"EA Perez","year":"2017","unstructured":"Perez EA, Barrios C, Eiermann W, Ellis P, et al. Trastuzumab Emtansine with or without Pertuzumab versus Trastuzumab plus Taxane for human epidermal growth factor receptor 2\u2013positive, advanced breast Cancer: primary results from the phase III MARIANNE study. J Clin Oncol. 2017;35(2):141\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"6132_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(18)30001-9","volume":"19","author":"L Gianni","year":"2018","unstructured":"Gianni L, Bisagni G, Colleoni M, Viale G, et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label,phase 2 study. Lancet Oncol. 2018;19(2):249\u201356.","journal-title":"Lancet Oncol."},{"issue":"2","key":"6132_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10549-017-4653-2","volume":"169","author":"J Foldi","year":"2017","unstructured":"Foldi J, Mougalian S, Silber A, Pusztai L, et al. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer. Breast Cancer Res Treat. 2017;169(2):333\u201340.","journal-title":"Breast Cancer Res Treat"},{"key":"6132_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1634\/theoncologist.2016-0268","volume":"22","author":"JC Singh","year":"2017","unstructured":"Singh JC, Mamtani A, Barrio A, Dang C, et al. Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with Trastuzumab and Pertuzumab in patients with HER2-positive early stage breast Cancer: a single center experience. Oncologist. 2017;22:139\u201343.","journal-title":"Oncologist"},{"issue":"1","key":"6132_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-016-3866-0","volume":"158","author":"SR Tiwari","year":"2016","unstructured":"Tiwari SR, Mishra P, Raska P, Montero AJ, et al. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab\/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. Breast Cancer Res Treat. 2016;158(1):189\u201393.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"6132_CR26","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1634\/theoncologist.2017-0079","volume":"22","author":"M Andersson","year":"2017","unstructured":"Andersson M, L\u00f3pez-Vega JM, Petit T, Perez EA, et al. Efficacy and safety of Pertuzumab and Trastuzumab administered in a single infusion bag, followed by Vinorelbine: VELVET cohort 2 final results. Oncologist. 2017;22(10):1160\u20138.","journal-title":"Oncologist."},{"issue":"1","key":"6132_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13058-016-0773-6","volume":"18","author":"EA Perez","year":"2016","unstructured":"Perez EA, L\u00f3pez-Vega JM, Petit T, Andersson M, et al. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET cohort 1 final results. Breast Cancer Res. 2016;18(1):126.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"6132_CR28","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1200\/JCO.2014.57.1745","volume":"33","author":"C Dang","year":"2015","unstructured":"Dang C, Iyengar N, Datko F, Hudis C, et al. Phase II study of paclitaxel given once per week along with Trastuzumab and Pertuzumab in patients with human epidermal growth factor receptor 2\u2013positive metastatic breast Cancer. J Clin Oncol. 2015;33(5):442\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"6132_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/1078155215578494","volume":"22","author":"BD Dao","year":"2015","unstructured":"Dao BD, Ho H, Quintal LN. Combination pertuzumab, trastuzumab,and taxane for metastatic breast cancer after first progression: a single institution\u2019s experience. J Oncol Pharm Pract. 2015;22(2):261\u20134.","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"6132_CR30","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","volume":"28","author":"J Baselga","year":"2010","unstructured":"Baselga J, Gelmon KA, Verma S, Gianni L, et al. Phase II trial of Pertuzumab and Trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast Cancer that progressed during prior Trastuzumab therapy. J Clin Oncol. 2010;28(7):1138\u201344.","journal-title":"J Clin Oncol"},{"issue":"9","key":"6132_CR31","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/1078-0432.CCR-07-4636","volume":"14","author":"CC Portera","year":"2008","unstructured":"Portera CC, Walshe JM, Rosing DR, Swain SM, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive HER2-positive metastatic breast cancer. Clin Cancer Res. 2008;14(9):2710\u20136.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6132_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40801-016-0102-5","volume":"4","author":"NJ Robert","year":"2017","unstructured":"Robert NJ, Goertz HP, Chopra P, Antao V, et al. HER2-positive metastatic breast Cancer patients receiving Pertuzumab in a community oncology practice setting:treatment patterns and outcomes. Drugs Real World Outcomes. 2017;4(1):1\u20137.","journal-title":"Drugs Real World Outcomes"},{"key":"6132_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.breast.2017.12.012","volume":"38","author":"S De Placido","year":"2018","unstructured":"De Placido S, Giuliano M, Schettini F, Arpino G, et al. Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. Breast. 2018;38:86\u201391.","journal-title":"Breast."},{"issue":"14","key":"6132_CR34","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.2013.52.6590","volume":"32","author":"KD Miller","year":"2014","unstructured":"Miller KD, Di\u00e9ras V, Harbeck N, Burris HA, et al. Phase IIa trial of Trastuzumab Emtansine with Pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast Cancer. J Clin Oncol. 2014;32(14):1437\u201344.","journal-title":"J Clin Oncol"},{"key":"6132_CR35","doi-asserted-by":"publisher","first-page":"6106041","DOI":"10.1155\/2018\/6106041","volume":"2018","author":"N Hussain","year":"2018","unstructured":"Hussain N, Said ASA, Khan Z. Safety assessment of neoadjuvant Pertuzumab combined with Trastuzumab in nonmetastatic HER2-positive breast Cancer in postmenopausal elderly women of South Asia. Int J Breast Cancer. 2018;2018:6106041.","journal-title":"Int J Breast Cancer"},{"key":"6132_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/jnci\/dju203","volume":"106","author":"A Nagayama","year":"2014","unstructured":"Nagayama A, Hayashida T, Jinno H, et al. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast Cancer: a network meta-analysis. J Natl Cancer Inst. 2014;106:9 https:\/\/doi.org\/10.1093\/jnci\/dju203 .","journal-title":"J Natl Cancer Inst"},{"key":"6132_CR37","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1158\/1078-0432.CCR-14-2728","volume":"21","author":"M Giuliano","year":"2015","unstructured":"Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, et al. Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy. Clin Cancer Res. 2015;21:3995\u20134003.","journal-title":"Clin Cancer Res"},{"key":"6132_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/1471-2407-13-241","volume":"13","author":"M Takada","year":"2013","unstructured":"Takada M, Higuchi T, Tozuka K, Takei H, Haruta M, Watanabe J, et al. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. BMC Cancer. 2013;13:241.","journal-title":"BMC Cancer"},{"key":"6132_CR39","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.cellsig.2005.12.007","volume":"18","author":"CM Warren","year":"2006","unstructured":"Warren CM, Landgraf R. Signaling through ERBB receptors: multiple layers of diversity and control. Cell Signal. 2006;18:923\u201333.","journal-title":"Cell Signal"},{"key":"6132_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0896-6273(02)01128-5","volume":"37","author":"SA Crone","year":"2003","unstructured":"Crone SA, Negro A, Trumpp A, et al. Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system. Neuron. 2003;37:29\u201340.","journal-title":"Neuron."},{"key":"6132_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/sj.bjc.6602875","volume":"94","author":"I Laux","year":"2006","unstructured":"Laux I, Jain A, Singh S, et al. Epidermal growth factor receptor dimerization status determines skin toxicity to HER kinase targeted therapies. Br J Cancer. 2006;94:85\u201392.","journal-title":"Br J Cancer"},{"key":"6132_CR42","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1006\/excr.2001.5390","volume":"271","author":"IY De Potter","year":"2001","unstructured":"De Potter IY, Poumay Y, Squillace KA, et al. Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation. Exp Cell Res. 2001;271:315\u201328.","journal-title":"Exp Cell Res"},{"issue":"17","key":"6132_CR43","doi-asserted-by":"publisher","first-page":"10261","DOI":"10.1074\/jbc.273.17.10261","volume":"273","author":"YY Zhao","year":"1998","unstructured":"Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem. 1998;273(17):10261\u20139.","journal-title":"J Biol Chem"},{"key":"6132_CR44","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1002\/ijc.28234","volume":"133","author":"A Valachis","year":"2013","unstructured":"Valachis A, Nearchou A, Polyzos NP. Cardiac toxicity in breast cancer patients treated with dual HER2 blockade. Int J Cancer. 2013;133:2245\u201352 https:\/\/doi.org\/10.1002\/ijc.28234 .","journal-title":"Int J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6132-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6132-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6132-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T22:23:58Z","timestamp":1695335038000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6132-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6132"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6132-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,21]]},"assertion":[{"value":"21 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research work constitutes a meta-analysis of published data and does not include any studies with human participants or animals performed by any of the authors. Hence, no informed consent was required to perform this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"973"}}